)
Affimed (AFMD) investor relations material
Affimed Leerink’s Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leadership and strategic direction
New CEO with extensive experience in biotech fundraising, public offerings, and clinical development, having led multiple companies through significant financing and clinical milestones.
Pipeline prioritization is a key focus, with decisions influenced by investor input and commercial potential of each asset.
AFM24 and AFM28 are receiving the most attention from investors and partners due to promising data and large unmet needs.
Acimtamig may be deprioritized due to its smaller commercial potential, though it remains a topic in partnering discussions.
Investor and partner interests are aligned, with both groups seeking late-phase, differentiated programs.
Clinical program updates and data
AFM24 in combination with atezolizumab shows a 21% ORR and 5.6 months PFS in EGFR wild type NSCLC, and 24% ORR with similar PFS in EGFR mutant patients.
Higher exposure to AFM24 correlates with improved efficacy across ORR, PFS, and OS, prompting a move to a 720 mg dose cohort, pending regulatory approval.
Next AFM24 cohort will exclude prior taxane exposure to potentially enrich for better PFS outcomes.
AFM28 in AML has shown a 40% composite CR rate at 300 mg, with response durations of 2.5–6.5 months, outperforming recent regulatory benchmarks.
Dose escalation for AFM28 continues, with further data expected 6–9 months after enrolling the next cohort.
Differentiation and competitive positioning
NK cell engager approach enables a wider therapeutic index, reducing toxicity compared to T-cell engagers, CAR-Ts, and ADCs targeting CD123.
AFM24 and AFM28 demonstrate lower on-target toxicity, with no typical EGFR-related skin or mucosal side effects.
Both programs are seen as optimal for difficult targets with narrow therapeutic windows, validated by similar approaches from competitors.
Acimtamig, in combination with Artiva’s NK cells, maintains high CR and ORR rates in double refractory Hodgkin’s lymphoma, with durability data pending.
Commercial viability and scalability are prioritized in development decisions, especially regarding NK cell sourcing and dosing regimens.
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)